Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 18494354)

1.

Adjuvant chemotherapy for stage II colon cancer.

Kopetz S, Freitas D, Calabrich AF, Hoff PM.

Oncology (Williston Park). 2008 Mar;22(3):260-70; discussion 270, 273, 275. Review.

2.

Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer.

Teufel A, Gerken M, Hartl J, Itzel T, Fichtner-Feigl S, Stroszczynski C, Schlitt HJ, Hofstädter F, Klinkhammer-Schalke M.

BMC Cancer. 2015 May 20;15:419. doi: 10.1186/s12885-015-1404-9.

3.

Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients.

Dienstmann R, Salazar R, Tabernero J.

J Clin Oncol. 2015 Jun 1;33(16):1787-1796. Epub 2015 Apr 27. Review.

PMID:
25918287
4.

Stage II colon cancer.

Church DN, Midgley R, Kerr DJ.

Chin Clin Oncol. 2013 Jun;2(2):16. doi: 10.3978/j.issn.2304-3865.2013.03.03.

5.

Oncotype DX® colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence.

You YN, Rustin RB, Sullivan JD.

Surg Oncol. 2015 Jun;24(2):61-66. doi: 10.1016/j.suronc.2015.02.001. Epub 2015 Feb 14. Review.

PMID:
25770397
6.

Evaluation of patient registries supporting reimbursement decisions: the case of oxaliplatin for treatment of stage III colon cancer.

Mohseninejad L, van Gils C, Uyl-de Groot CA, Buskens E, Feenstra T.

Value Health. 2015 Jan;18(1):84-90. doi: 10.1016/j.jval.2014.10.008.

PMID:
25595238
7.

Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy.

Fang SH, Efron JE, Berho ME, Wexner SD.

J Am Coll Surg. 2014 Nov;219(5):1056-69. doi: 10.1016/j.jamcollsurg.2014.09.010. Epub 2014 Sep 19. Review. No abstract available.

PMID:
25440029
8.

Should I continue an experimental drug?

Helft PR.

Oncology (Williston Park). 2014 Oct;28(10):893-4. No abstract available.

9.

Evolving role of gene expression signatures as biomarkers in early-stage colon cancer.

Goel G.

J Gastrointest Cancer. 2014 Dec;45(4):399-404. doi: 10.1007/s12029-014-9634-7.

PMID:
24989938
10.

Current status of gene expression profiling to assist decision making in stage II colon cancer.

Chee CE, Meropol NJ.

Oncologist. 2014 Jul;19(7):704-11. doi: 10.1634/theoncologist.2013-0471. Epub 2014 May 28.

11.

Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study.

Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, Karaagac M, Gündüz S, Isik N, Uygun K.

Tumori. 2014 Mar-Apr;100(2):143-8. doi: 10.1700/1491.16397.

12.

Administration of adjuvant oxaliplatin to patients with stage III colon cancer is affected by age and hospital.

van Erning FN, Bernards N, Creemers GJ, Vreugdenhil A, Lensen CJ, Lemmens VE.

Acta Oncol. 2014 Jul;53(7):975-80. doi: 10.3109/0284186X.2013.878470. Epub 2014 Jan 21. No abstract available.

PMID:
24446744
13.

[Compliance with FOLFOX4 for Stage III colon cancer in the adjuvant setting].

Okazaki S, Sugawara K, Hashizume E, Abe M, Hagiwara M, Aiso T, Shirahata Y, Chin M, Suzuki A, Kuriya Y.

Gan To Kagaku Ryoho. 2014 Jan;41(1):59-63. Japanese.

PMID:
24423953
14.

Personalized medicine in the adjuvant chemotherapy of stage II colon cancer--are we there yet?

Lee JJ, Chu E.

Oncology (Williston Park). 2013 Aug;27(8):754, 756-8. No abstract available.

15.

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ; ACCENT Collaborative Group.

Clin Colorectal Cancer. 2013 Sep;12(3):179-87. doi: 10.1016/j.clcc.2013.04.004. Epub 2013 Jun 27.

16.

Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.

Oh SY, Kim do Y, Kim YB, Suh KW.

World J Surg. 2013 Oct;37(10):2497-503. doi: 10.1007/s00268-013-2120-8.

PMID:
23754140
17.

Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.

McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ.

J Clin Oncol. 2013 Jul 10;31(20):2600-6. doi: 10.1200/JCO.2013.49.6638. Epub 2013 Jun 3.

18.

Managing choices for older patients with colon cancer: adjuvant therapy.

Wu C, Goldberg RM.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e190.

19.

Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study.

Kim KY, Cha IH, Ahn JB, Kim NK, Rha SY, Chung HC, Roh JK, Shin SJ.

J Surg Oncol. 2013 May;107(6):613-8. doi: 10.1002/jso.23290. Epub 2012 Nov 28.

PMID:
23592499
20.

Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients.

Lund JL, Stürmer T, Sanoff HK, Brookhart A, Sandler RS, Warren JL.

Cancer. 2013 Jun 1;119(11):2038-47. doi: 10.1002/cncr.27991. Epub 2013 Mar 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk